Tet1 Is Dispensable for Maintaining Pluripotency and Its Loss Is Compatible with Embryonic and Postnatal Development

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.stem.2011.07.010">http://dx.doi.org/10.1016/j.stem.2011.07.010</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://hdl.handle.net/1721.1/92553">http://hdl.handle.net/1721.1/92553</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
</tbody>
</table>
Tet1 Is Dispensable for Maintaining Pluripotency and Its Loss Is Compatible with Embryonic and Postnatal Development

Meelad M. Dawlaty,1 Kibibi Ganz,1 Benjamin E. Powell,1 Yueh-Chiang Hu,1 Styliani Markoulaki,1 Albert W. Cheng,1,2,3 Qing Gao,1 Jongpil Kim,1 Sang-Woon Choi,4 David C. Page,1,2,5 and Rudolf Jaenisch1,2,*

1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
2Department of Biology
3Computational and Systems Biology Program
Massachusetts Institute of Technology, Cambridge, MA 02142, USA
4Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
5Howard Hughes Medical Institute
*Correspondence: jaenisch@wi.mit.edu
DOI 10.1016/j.stem.2011.07.010

SUMMARY

The Tet family of enzymes (Tet1/2/3) converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Mouse embryonic stem cells (mESCs) highly express Tet1 and have an elevated level of 5hmC. Tet1 has been implicated in ESC maintenance and lineage specification in vitro but its precise function in development is not well defined. To establish the role of Tet1 in pluripotency and development, we have generated Tet1 mutant mESCs and mice. Tet1−/− ESCs have reduced levels of 5hmC and subtle changes in global gene expression, and are pluripotent and support development of live-born mice in tetraploid complementation assay, but display skewed differentiation toward trophectoderm in vitro. Tet1 mutant mice are viable, fertile, and grossly normal, though some mutant mice have a slightly smaller body size at birth. Our data suggest that Tet1 loss leading to a partial reduction in 5hmC levels does not affect pluripotency in ESCs and is compatible with embryonic and postnatal development.

INTRODUCTION

DNA methylation is a well-defined epigenetic modification that is essential for normal development and regulation of gene expression. Mechanisms of establishment and maintenance of DNA methylation are well characterized. Conversely, little is known about mechanisms that underlie DNA demethylation (Ooi and Bestor, 2008; Wu and Zhang, 2010). Passive demethylation has been proposed as simply the failure of the maintenance methyltransferase (DNMT1) upon DNA replication (Dean et al., 2003). This model, however, cannot explain examples of replication-independent DNA demethylation most notably observed in the paternal pronucleus in the zygote and during reprogramming of primordial germ cells. A number of models of active demethylation have been proposed, from simple excision of the methyl group to more intricate pathways that involve mechanisms of DNA repair (Wu and Zhang, 2010).

Recently, the Ten-eleven translocation (Tet) family of methyl dioxygenases (Tet1, Tet2, and Tet3) has been implicated in DNA demethylation (Ito et al., 2010; Tahiliani et al., 2009). These enzymes have 2-oxoglutarate (2OG)-and Fe-(II) dependent oxygenase activity and catalyze the hydroxylation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Given that DNMT1 recognizes 5mC poorly, this modification could lead to passive demethylation (Valinluck and Sowers, 2007). It has also been proposed that 5hmC could be involved in active DNA demethylation whereby it undergoes spontaneous or enzymatic conversion to cytosine, or serves as an intermediate that can be subjected to DNA repair and then replaced with cytosine (Ooi and Bestor, 2008). Indeed, a recent study reports that Tet1-mediated hydroxylation of 5mC promotes active DNA demethylation in the adult brain through a process that requires base excision repair pathway involving the activation-induced deaminase (AID)/apolipoprotein B mRNA-editing enzyme complex (APOBEC) family of cytidine deaminases (Guo et al., 2011).

Though the Tet enzymes are expressed in various tissues, the 5hmC base is particularly abundant in Purkinje neurons (Kriaucionis and Heintz, 2009) and mouse embryonic stem cells (mESCs) (Ito et al., 2010; Tahiliani et al., 2009). Recently it has been shown that Tet1 and 5hmC are enriched at transcriptional start sites of CpG rich promoters and gene bodies in ESCs, where it promotes DNA demethylation and transcription. Interestingly, Tet1 also binds to polycomb target gene promoters and plays a role in repression of polycomb-controlled developmental regulators (Williams et al., 2011; Wu et al., 2011). These findings suggest that Tet1 could have an important functional role in maintaining pluripotency and development. Using small hairpin RNAs (shRNAs) to knockdown Tet1 in mESCs and one-cell stage embryos, one study reported that Tet1 maintains expression of Nanog and is required for mESC self-renewal and inner cell mass (ICM) specification (Ito et al., 2010). Conversely, another study found that Tet1 and Tet2 are downstream targets of Oct4, but knockdown of neither of these genes affects Nanog expression or the pluripotent state of ESCs (Koh et al., 2011b). However, the latter study reported that Tet1 depletion skews differentiation toward endoderm-mesoderm lineages.
Figure 1. Generation of Tet1 Knockout Mouse ESCs

(A) Schematic of gene targeting strategy applied to generate Tet1 knockout mouse embryonic stem cells (mESCs). H stands for the properly targeted 2-lox conditional/hypomorphic allele.

(B–F) Southern blot confirmation of properly targeted Tet1 mESCs clones. Analysis of Tet1+/H clones (B&C) and Tet1+/H clones is shown in (E). Excision of exon 4 by transient Cre recombinase expression to generate Tet1+/– mESCs (D) or Tet1+/+ cells is shown in (F). Note that the clones shown in these blots are representative clones and do not correspond numerically with each other.
in a teratoma assay. Together, these findings imply a potential requirement for Tet1 in maintenance of pluripotency and normal embryogenesis and warrant further elucidation of the role of Tet1 in pluripotency and development.

RESULTS

Generation of Tet1 Knockout ESCs

To define the role of Tet1 in maintaining pluripotency and to establish its essential functions during development, it is important to utilize a system that stably and completely depletes Tet1 in mESCs. To this end, we applied gene targeting to generate Tet1 knockout mESCs. We flanked exon 4 of Tet1 with loxP sites to generate a conditional 2-lox allele (H), which was subsequently excised with transient Cre recombinase expression to produce a Tet1 knockout (−) allele (Figure 1A). Loss of exon 4 in this allele leads to an out of frame fusion of exons 3 and 5, yielding an unstable truncated product lacking the catalytic domain of Tet1. Upon sequential targeting of each allele of Tet1 followed by Cre-mediated excision of exon 4, we obtained Tet1−/− mESCs (Figures 1B–1F). We confirmed the absence of transcripts containing exon 4 by RT-qPCR (Figure 1G) and complete depletion of Tet1 protein by western blot (Figure 1H).

To measure the presence of any residual transcripts, we used primers spanning the last exons of the gene. As expected for this knockout strategy, we detected some level of residual full-length transcript, but none contained exon 4. Moreover, we did not detect any residual low-molecular weight, truncated proteins in Tet1−/− mESCs by western blot, suggesting that indeed Tet1 is completely depleted in these cells.

Tet1 Loss in ESCs Leads to Partial Reduction in 5hmC and Subtle Changes in Global DNA Methylation and Gene Expression

Given the role of Tet1 in converting 5mC to 5hmC, we wanted to determine if loss of Tet1 affects 5mC levels in Tet1 knockout mESCs. To this end we measured global 5mC levels in genomic DNA from Tet1+/+, Tet1+/−, and Tet1−/− mESCs by a dot blot assay using an antibody against 5mC. Consistent with previous studies using Tet1 knockdown shRNAs (Itô et al., 2010; Tahiliani et al., 2009), we found that loss of Tet1 did not lead to complete depletion of 5mC levels, but rather to a level reduced by ~35% (Figures 2A and 2B). To quantify 5mC levels in a locus-specific fashion, we performed hydroxylated hydroxymethyl-sensitive qPCR (glucMS-qPCR) using HpaII and MspI restriction enzymes and primers in Cpg islands of genes known to contain 5mC (Ficz et al., 2011), and we found that, compared with wild-type mESCs, Tet1−/− mESCs had a significant reduction in 5mC in these Cpg islands (Figure 2C), which correlated with a less profound but considerable increase in 5mC content (Figure 2D). To determine how global 5mC levels are affected in the absence of Tet1, we quantified the genomic 5mC content in Tet1+/+ and Tet1−/− mESCs by liquid chromatography/mass spectrometry (LC/MS) (Figure 2E) and found a slight increase of 5mC levels from 4.89% in wild-type cells to 5.15% in Tet1−/− cells. These analyses suggest that loss of Tet1 in ESCs leads to a partial reduction in 5mC levels with a very subtle effect on global DNA methylation. This also suggests that Tet1 is likely not the only enzyme catalyzing 5mC generation in ESCs, and that other Tet family members or pathways participate in this process or compensate for Tet1 loss. Although Tet1 loss did not lead to induction of Tet2 or Tet3 expression in Tet1−/− mESCs, shRNA-mediated knockdown of Tet2 in these cells further reduced 5mC levels (Figures S1A–S1D available online).

To examine whether Tet1 loss and reduction in 5mC levels influence gene expression of ESCs, we analyzed RNA from two independent Tet1−/− and wild-type ESCs by microarray. We found that 221 genes (mostly genes involved in developmental processes) were significantly deregulated by 2-fold or more in both knockout ESCs compared with wild-type mESCs (Figure 2F). While 60% of genes (137 genes) were downregulated, 40% (84 genes) were upregulated (Figure S2), suggesting that Tet1 has both activating and repressive effects on gene expression, which is consistent with the current notion of dual roles for Tet1 in transcriptional regulation (Williams et al., 2011; Wu et al., 2011).

Tet1 Knockout ESCs Are Pluripotent and Can Support Development of the Embryo Progeny in a Tetraploid Complementation Assay

To establish whether depletion of Tet1 influences the pluripotency of ESCs, we first examined the morphology and expression of pluripotency markers in Tet1 knockout mESCs cultured either on feeders (Figure 3A) or on gelatin (Figure S3A). Under both conditions and over the course of multiple passages (>15), mutant cells maintained a normal undifferentiated ESC morphology, stained positive for alkaline phosphatase, and expressed the pluripotency markers Oct4, Nanog, and Sox2 (Figures 3A–3C, Figure S3B). A similar unperturbed ESC morphology and pluripotency marker expression was observed for Tet1 knockout ESCs subjected to a 60% shRNA-mediated Tet2 knockdown (Figures S1E–S1G). Tet1 knockout ESCs were capable of forming embryoid bodies (EBs) and could differentiate in vitro to neural progenitor cells (NPCs). However, knockout EBs had altered expression of the lineage specification markers Brachyury and Pax6, and the overall yield of EB formation from knockout cells was substantially low due to their increased tendency to attach to the plastic surface and differentiate as early as day 6 of Leukemia Inhibitory Factor (LIF) withdrawal (Figures S3C–S3E), suggesting that Tet1 loss may influence the differentiation potential of ESCs in vitro.

To determine if Tet1 knockout mESCs are fully pluripotent and can differentiate to support development of the embryo proper, we performed a tetraploid complementation assay. This is the most stringent test for assessing pluripotency, because the cells of the recipient tetraploid (4n) blastocyst can only contribute to
the trophectoderm and not the epiblast, thus generating embryos that are exclusively derived from the injected diploid mESCs (Eggan et al., 2001; Zhao et al., 2009). We injected two independent Tet1 knockout mESCs, one heterozygote, and one wild-type mESC clone into B6D2F1 x B6D2F1 4n blastocysts, which were subsequently transferred into pseudopregnant female mice. We performed cesarean section to deliver the pups and found that Tet1 knockout, heterozygote, and wild-type mESC clones developed into full-term live mice with similar efficiencies (Figures 3D–3G). Tet1 knockout pups appeared indistinguishable from wild-type pups (Figure 3D) and were able to move and breathe at birth. Attempts at fostering these pups to monitor their postnatal development failed because both wild-type and Tet1 knockout mice died within hours of delivery. Low rate of postnatal survival is a common limitation of the tetraploid complementation assay (Eggan et al., 2001). Southern blot analysis of tail DNA obtained from these pups confirmed that they were derived from Tet1 knockout mESCs (Figure 3E). Autopsy and histological analyses failed to reveal any abnormalities in knockout pups (Figure 3G). These findings confirm that Tet1 knockout cells are pluripotent and that loss of Tet1 does not lead to defects that would interfere with postimplantation embryonic development to birth.

Consistent with these results, Tet1−/− ESCs were shown to be pluripotent in a teratoma assay forming tumors with differentiated cells derived from the three embryonic germ layers (Figure 3H). However, Tet1 knockout teratomas were large and hemorrhagic, which is likely due to excessive numbers of trophoblast-derived cells that form lumens and promote more blood flow from the host (Figure 3I). Thus, loss of Tet1 seems to skew differentiation toward extraembryonic lineages in the teratoma assay, consistent with previous findings with Tet1 knockdown ESCs (Koh et al., 2011a). To determine whether Tet1 loss affects differentiation also in the early embryo, we injected GFP-labeled Tet1 knockout ESCs into eight-cell-stage wild-type (2n) embryos and traced their distribution until the blastocyst stage, where we could only locate GFP-positive cells in the center ICM region of the blastocyst and not in the outer trophoderm layer (Figure 3J). When the cells were injected into wild-type blastocysts and implanted into pseudopregnant females, the GFP-labeled Tet1 knockout ESCs were exclusively found in the embryo proper and no cells were detected in the placenta (Figure 3K). Thus, the findings from these assays suggest that unlike in the teratoma assay, Tet1 loss seems not to skew differentiation toward trophoderm in vivo in the context of a developing embryo.

Overtly uncompromised differentiation of Tet1 knockout ESCs is also supported by the 4n complementation assay, which resulted in birth of “all-knockout ESC mice.” However, since some extraembryonic layers are contributed by the host blastocyst, this assay cannot assess the function of Tet1 in the trophoderm lineage. Therefore, to unambiguously establish the function of Tet1 in embryogenesis, we generated homozygous mutant mice from intercrossing heterozygous animals.

**Tet1−/− Mice Are Viable and Fertile but Vary in Body Size**

We injected Tet1−/− v6.5 male mESCs into B6D2F1 blastocysts to generate male chimeras, which were bred with C57BL6 females to obtain heterozygote mice that were grossly normal and fertile (Figure 4A). To generate Tet1 homozygous knockout animals, we intercrossed heterozygote animals at 6–8 weeks of age. All breeding pairs produced normal-sized litters of five to nine pups. However, each litter contained an average of two pups that were considerably smaller in body size than their littermates (Figure 4B). We determined the genotypes of all litters by Southern blot (Figure 4C) and found that wild-type, heterozygous, and homozygous knockout mice were readily born at the expected 1:2:1 Mendelian ratio, suggesting that no Tet1 knockout embryos were lost in utero (Figure 4D). About 75% of the homozygous mutant pups had a smaller body size (13/17 pups) at birth. Both male and female mutant mice weighed significantly less than wild-type animals at 3 weeks of age but seemed to gain weight when growing older (Figure 4E). Consistent with the slightly reduced postnatal body size, we found that E12.5 knockout embryos from a Tet1−/− x Tet1−/− cross also vary in size, ranging from 24 to 32 tail somite pairs, compared with heterozygous and wild-type littermates that range between 30 and 34 tail somite pairs (Figure 4F). This suggests that loss of Tet1 during embryogenesis leads to a mild developmental delay that is partially penetrant, producing both normal-sized and smaller embryos.

With the exception of variability in body size and weight, homozygote animals were grossly normal and appeared healthy. Blood analyses of 4-week-old wild-type and knockout mice for CBC and liver enzyme functions showed no major differences except for a slight decrease in the number of neutrophils in knockout animals (Figure S4). Moreover, gonads of both sexes of E13.5 knockout embryos contained mouse vasa homolog (mvh)-positive germ cells (Figure 4G). Mating of homozygous mutant males and females produced viable progeny (Figures 4H–4J) though the average litter size (three to six pups) seemed to be smaller than the average litter size of heterozygous parents.
Figure 3. Tet1 Knockout ESCs Are Pluripotent and Support Postimplantation Embryonic Development in Tetraploid Complementation Assay

(A) Alkaline phosphatase staining and morphological appearance of Tet1 mESCs of indicated genotypes on feeders.

(B) Immunostaining for pluripotency markers Oct4 and Nanog.

(C) Relative expression of core pluripotency network genes Oct4, Sox2, and Nanog measured by quantitative RT-PCR. Data are normalized to GAPDH. Error bars represent SEM.

---

**Table**

<table>
<thead>
<tr>
<th>mESC Genotype</th>
<th>Embryos Transferred</th>
<th>Embryos Implanted</th>
<th>Reabsorbed/partially developed</th>
<th>Live delivered pups (E21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>++/+</td>
<td>40</td>
<td>10</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>++/− #3</td>
<td>40</td>
<td>13</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>++/− #34</td>
<td>60</td>
<td>7</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>++/− #19</td>
<td>80</td>
<td>23</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

---

**Figure 3.** Tet1 Knockout ESCs Are Pluripotent and Support Postimplantation Embryonic Development in Tetraploid Complementation Assay

(A) Alkaline phosphatase staining and morphological appearance of Tet1 mESCs of indicated genotypes on feeders.

(B) Immunostaining for pluripotency markers Oct4 and Nanog.

(C) Relative expression of core pluripotency network genes Oct4, Sox2, and Nanog measured by quantitative RT-PCR. Data are normalized to GAPDH. Error bars represent SEM.
(five to nine pups). Since Tet1 is expressed in germ cells (Hajkova et al., 2010), the role of Tet1 in gametogenesis and fertility requires further investigation.

**DISCUSSION**

Ever since the implication of Tet proteins in DNA demethylation and maintenance of pluripotency, research has focused on establishing the biological relevance of these proteins (Ito et al., 2010; Koh et al., 2011a; Tahiliani et al., 2009). Targeted deletion of Tet1 in ESCs and generating Tet1 knockout mice has provided a clean and stable system to study Tet1 function in pluripotency and development. Here, we have provided three lines of evidence to establish that Tet1 is dispensable for ESC maintenance, and its loss, compatible with embryonic development and postnatal survival. First, Tet1−/− mESCs remain undifferentiated in vitro and express pluripotency markers Oct4, Sox2, and Nanog and can contribute to tissues of the three embryonic germ layers in teratomas. Second, Tet1−/− mESCs can support normal development of the embryo proper in a tetraploid complementation assay, suggesting that they are pluripotent and can support postimplantation embryonic development. Third, Tet1 homozygous mutant mice are viable and fertile and born at a normal Mendelian ratio, albeit with slight reduction in body size, establishing that loss of Tet1 does not interfere with postnatal survival.

Our findings expand upon the previously published in vitro studies on Tet1 and bring new insights into defining the actual physiological requirements of the gene in pluripotency and development. Previously reported shRNA-based in vitro knockdown studies (Ito et al., 2010; Koh et al., 2011a), together with recent findings on the dual roles of Tet1 in transcriptional regulation and repression of polycomb-controlled developmental genes (Williams et al., 2011; Wu et al., 2011), suggested that Tet1 is likely a key player in ESC maintenance, lineage specification, and embryogenesis. One report showed that Tet1 knockdown in mESCs diminished Nanog expression and impaired self-renewal (Ito et al., 2010). We did not observe such a phenotype in Tet1−/− cells, and it is possible that ESC background differences and/or off target effects of shRNAs may explain these differences (Williams et al., 2011). Consistent with our findings, another study using a different set of shRNAs to knock down Tet1 and Tet2 reported that depletion of these proteins does not affect Nanog expression, ESC self-renewal, or pluripotency (Koh et al., 2011b). However, this study found that Tet1 deficiency skews lineage specification toward mesendoderm and trophoblast at the expense of neuroectoderm in a teratoma assay leading to formation of large hemorrhagic tumors. Although we observed more hemorrhage and an increase in trophoblast-like cells in Tet1 knockout teratomas, we did not observe any overt reduction in the formation of neuroectoderm or contribution to placenta upon injection of mutant ESCs into wild-type blastocysts. EBs generated from Tet1 knockout ESCs were capable of forming NPs in culture, even though the overall yield of EB formation from knockout cells was substantially lower due to their increased tendency to attach to the plastic surface and differentiate.

The generation of viable mutant mice argues against profound defects in lineage specification due to loss of Tet1. It is possible, therefore, that the teratoma assay or differentiation to EBs uncovered abnormalities that are only detectable in vitro and do not overtly affect embryonic development. We consider two possibilities to explain the seemingly normal in vivo development of mutant embryos and the in vitro differentiation abnormalities of mutant ESCs. (1) Tet1 knockout ESCs exhibit skewed differentiation in nonphysiological conditions such as a teratoma or within in vitro assays. (2) Tet1 knockout ESCs have lineage specification defects, but any such defects are less pronounced in the context of an embryo compared with a teratoma or EB and are compatible with embryogenesis, consistent with the failure of mutant ESCs to contribute to the trophoblast lineage in vivo.

The generation of viable and fertile Tet1 mutant mice unequivocally indicated that Tet1 deficiency does not prevent embryonic and postnatal development. However, the slight reduction in postnatal body size and weight of Tet1 knockout mice is consistent with Tet1 playing a role during development. Given the evidence that Tet1 regulates gene expression, particularly by repressing polycomb-regulated developmental genes (Williams et al., 2011; Wu et al., 2011), it is possible that subtle deregulation of these developmental regulators interferes with timely progression of embryogenesis and triggers a mild developmental delay. Because normal-sized knockout mice were generated by tetraploid complementation, it is possible that the role of Tet1 is more pronounced in placental function than in embryo development. However, further molecular and histological analysis of embryos at various stages during development is needed to establish if Tet1 loss leads to placental defects.

The three Tet enzymes are differentially regulated during early development. Tet3 is the only Tet enzyme expressed in the oocyte and zygote and is believed to have a role in paternal pronucleus demethylation (Iqbal et al., 2011; Wossidlo et al.,...
Targeted V6.5 Tet1\(^{−/−}\)

**Background:** 129/sv (M) X C57BL6 (F)

Male Chimeras

C57/BL6 females X Tet1\(^{−/−}\) male

Tet1\(^{−/−}\) male X Tet1\(^{−/−}\) female

Background (mix 129/C57BL6)

**A**

Schematic of crosses to generate Tet1 knockout mice.

**B**

Gross appearance of mice of indicated genotypes at various ages. Note that Tet1\(^{−/−}\) mice vary in size.

**C**

Genotype confirmation of mice from Tet1\(^{+/−}\) x Tet1\(^{+/−}\) cross by Southern blot.

**D**

Table summarizing the litter size and Mendelian ratio of Tet1\(^{−/−}\) mice.

**E**

Comparison of body size and weight between different genotypes.

**F**

Genotype confirmation of mice by tail somites and Mvh-positive germ cells in gonads of E12.5 embryos of similar size and developmental stage.

**G**

Comparison of testes and ovaries between different genotypes.

**H**

Comparison of 3-week-old weight (g) and 6-9-week-old weight (g) between different genotypes.

**I**

Progeny of Tet1\(^{−/−}\) (M) X Tet1\(^{−/−}\) (F).

**J**

Table of Litter size for different crosses.

---

**Figure 4. Tet1 Knockout Mice Are Viable but Vary in Body Size**

(A) Schematic of crosses to generate Tet1 knockout mice.

(B) Gross appearance of mice of indicated genotypes at various ages. Note that Tet1\(^{−/−}\) mice vary in size.

(C) Genotype confirmation of mice from Tet1\(^{+/−}\) x Tet1\(^{+/−}\) cross by Southern blot.

(D) Table summarizing the litter size and Mendelian ratio of Tet1\(^{−/−}\) mice.
2011). As the zygote develops, Tet3 levels diminish at the two-cell stage, and by the blastocyst stage, Tet1 and Tet2 are mainly expressed in the ICM. Both Tet1 and Tet2 are expressed in ESCs with Tet2 expression levels being 5-fold less than those of Tet1 (Koh et al., 2011a). We found that loss of Tet1 did not lead to induction of Tet2 and Tet3 mRNA levels in Tet1−/− mESCs. Given that Tet1 knockout ESCs have only a 35% reduction in 5hmC levels, it is likely that expression of Tet2 can compensate for Tet1 loss, consistent with the observation that a 60% knockdown of Tet2 in Tet1−/− ESCs further reduced 5hmC levels. Generation of double and triple knockout ESCs and mice for Tet genes will be important for dissecting the developmental roles of the different Tet proteins and 5hmC in vivo.

Embryonic development is a multistep and complex process. Although we have generated viable Tet1 knockout mice and have shown that loss of Tet1 is compatible with pluripotency and development, we cannot exclude subtle defects during development whose effects would manifest later in life, such as neurological and behavioral phenotypes, particularly given that loss of Tet1 is compatible with pluripotency and 5hmC expression in ESCs further reduced 5hmC levels. Generation of double and triple knockout ESCs and mice for Tet genes will be important for dissecting the developmental roles of the different Tet proteins and 5hmC in vivo.

**EXPERIMENTAL PROCEDURES**

**Generation and Culture of Tet1 Knockout Mouse ESCs**

Gene targeting procedures for generating Tet1 2-lox conditional/hypomorphic (H) and knockout (−) alleles were as previously described (Dawlaty and van Deursen, 2006). Briefly, Tet1 exon 4 and its flanking 100 base pair regions were amplified from v6.5 mESC DNA and cloned into multiple cloning site 1 (HindIII and KpnI) of pHTKVI901lrt-loxP vector. This was followed by cloning 4.2 kb 5′ homology arm and 4.3 kb 3′ homology arm into multiple cloning sites 2 (Hpal) and 3 (Smal and SacII) of this vector, respectively. Vector was linearized with Ncot and electroporated into v6.5 mESCs [mix background: 129/sv(M) x C57/BL6(F)] following standard procedures. Neo-resistant clones were picked and screened with 5′ and 3′ external probes and neo sequence internal probe. pPAC-Cre plasmid was electroporated into C57/BL6 females. Litters with agouti coat color germ line transmission were screened by Southern blot and PCR for presence of heterozygote mice. Six-week-old Tet1+/− animals were intercrossed to generate Tet1−/− mice. Pups were monitored daily for signs of poor health and weighed routinely after birth. Weight calculations and statistical analyses were performed using Prism Graphpad software. For analyses of blood, 400 μl of blood was collected retro-orbitally and analyzed at the Massachusetts Institute of Technology Department of Comparative Medicine Diagnostic and Comparative Pathology lab.

**Teratoma and Tetraploid Complementation Assays**

1 × 10⁶ mESCs were injected subcutaneously into SCID mice (Taconic). Three weeks after injection mice were euthanized and tumors were removed and fixed in formalin for two days. Then they were imbedded in paraffin, sectioned, and stained with hematoxylin and eosin for histological analysis. Tetraploid complementation assay was performed as explained before (Wernig et al., 2007). Briefly, two-cell stage B6D2F1 x B6D2F1 embryos were fused by electric pulse. Two hours later, properly fused embryos were separated and cultured in KSOM for two days until they developed into blastocysts. Ten to twelve mESCs were injected into each blastocyst following standard procedures. Twenty injected embryos were surgically transferred into the uterus of 2.5 d.p.c. pseudopregnant Swiss Webster female mice. Pregnant mice were sacrificed at day 21 and pups were immediately delivered by cesarean section method.

**Gene Expression Profile and Gene Ontology Analyses**

Microarray data were processed and quantile-normalized using Limma package in R (Smyth and Speed, 2003; Smyth, 2005). Probe values from the same gene were collapsed into median to get gene expression values. Relative expression was calculated as log2 ratio of gene expression in knockout cells to wild-type cells. For downstream analysis, only genes that have a signal of above 5 logs (base 2) in at least one sample and a minimum fold change of two in at least one knockout (versus wild-type) were retained. Gene ontology analysis was conducted using GeneGO with default parameters.

**ACCESION NUMBERS**

The gene array data sets reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, http://www.ncbi.nlm.nih.gov/geo (accession number GSE30748).

**SUPPLEMENTAL INFORMATION**

Supplemental Information for this article includes four figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.stem.2011.07.010.

**ACKNOWLEDGMENTS**

We thank Ruth Flannery for help with animal husbandry, Dongdong Fu for help with histology, J. Kwon and J. Love from Whitehead Genome Technology Core for help with microarray, and F. Soldner, G. Welstead, J. Staerk, K. Saha, B. Carey, and L. Medeiros for helpful discussions and critical reading of the manuscript. We are grateful to Dr. R. Bronson for analyzing histology slides and discussion on teratomas and Dr. M. Gehring for help with dot blots.

(E) Mouse body weights at the indicated ages. Error bars represent SD. Asterisks indicate statistically significant as compared with wild-type (t test, p < 0.05).

(F) Gross images of E12.5 embryos from Tet1−/+ x Tet1−/+ cross. Arrowheads point to knockout embryos. Genotype and number of tail somite pairs of embryos is tabulated to the left.

(G) Longitudinal sections of E13.5 gonads of indicated genotypes stained with antibody against the germ cell marker Mvh. Note that gonads were harvested from embryos of similar developmental stage and size.

(H) Gross images of progeny of Tet1 knockout parents at birth (cross of Tet1−/− x Tet1−/+).

(I) PCR genotyping confirmation of offspring of Tet1 knockout mice.

(J) Table summarizing average litter size from various crosses of 6- to 8-week-old Tet1 knockout mice.

See also Figure S4.
Tet1 in Pluripotency and Development

M.M.D is a Damon Runyon Fellow. B.E.P is supported by a Ph.D. fellowship from the Boehringer Ingelheim Fonds. A.W.C is supported by a Croucher scholarship. D.C.P is an HHMI investigator. R.J. is funded by NIH grants 5-R01-HDO45022, 5-R37-CA084198, and 5-R01-CA087869. R.J. is an adviser to Stemgent and cofounder of Fate Therapeutics.

Received: March 11, 2011
Revised: June 11, 2011
Accepted: July 19, 2011
Published: August 4, 2011

REFERENCES


